Form 4: Akero Therapeutics COO Jonathan Young Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 2,503 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold 2,503 shares of common stock on December 10, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $30.79, with individual transactions ranging from $30.76 to $30.93.
• Following the transaction, Mr. Young directly owns 203,783 shares of Akero Therapeutics common stock.
• Mr. Young also has indirect beneficial ownership of 60,000 shares held in irrevocable trusts for the benefit of his children.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• The 'sell-to-cover' policy is a standard mechanism used by many companies to manage tax liabilities for employees with stock-based compensation.
• The reported price range of $30.76 to $30.93 is within the expected range for a stock sale of this type.

Stakeholder Impact

• The sale of shares by the COO has a minimal impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Akero Therapeutics, Jonathan Young, stock sale, insider trading, Form 4, tax obligations, restricted stock units, beneficial ownership